You thought the Shark Tank was tough…

wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to be named the company with the most commercial potential at the 2018 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March, 30th 2018 

Finalists will be announced: April 9th, 2018 

Finalist Presentations BioHealth Capital Region Forum Event: April 24th, 2018

Submit an Application »

Read More

April 23-24  |  1 MedImmune Way, Gaithersburg MD 20878 

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Inova, Children’s National Health System, QIAGEN, Maryland Tech Council, University System of Maryland and MedImmune/AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

We are excited to bring you an exceptional line up of speakers. The program will feature sessions that focus on the Advancing Science and Accelerating Innovation.

Read More

BHI is working with several regional partners to cultivate local biohealth research talent and help those with interest and qualifications transition to industry.

This month, BHI is co-hosting with NCI, WorkSource Montgomery, and BioBuzz two PostDoc-Industry Connections Happy Hours enabling NCI postdocs and others at NIH to learn more about local opportunities in the region's biohealth industry. Industry participants are invited to attend these complimentary networking receptions and share their thoughts regarding career paths and opportunities in the field.

Registration is free but limited. RSVPs are required. Please RSVP using the following links:

2/15 - 6-8:00 p.m. - Waverly St. Gallery, Bethesda - RSVP here

2/20 - 5-7:00 p.m. - JHU Montgomery Campus, Rockville - RSVP here

Save the date: 6/20 - Industry Postdoc Hiring Event - NCI Rockville Campus

Questions/more information?

Read More

The company overcame early funding challenges with the help of influential backing.

Read More

Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd. (Haichang), to develop RX-0201 (Archexin®) for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Read More

eNeura, a Baltimore-based company that makes a device to treat migraines, closed a Series D investment round.

Read More

Maryland Technology Development Corp. made new seed investments in five Maryland startup companies, totaling $600,000.

TEDCO has invested hundreds of thousands of dollars in young, growing companies across the state. The state-backed organization has 137 active investments through its seed fund.

Read More

The University System of Maryland (USM) has selected NextStep Robotics, a startup company that has developed a personalized robotic therapy to help relieve discomforts of “foot drop” syndrome in recovering stroke patients, as recipient of the second investment from the recently established Maryland Momentum Fund.

Read More

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it has entered into an agreement with the Haemato Oncology Foundation for Adults in the Netherlands (HOVON) groupto initiate clinical trial startup activities. In the planned clinical trial, HOVON researchers will evaluate GlycoMimetics’ drug candidate, GMI-1271, in adults with newly diagnosed acute myeloid leukemia (AML) but who cannot tolerate intensive chemotherapy, as well as in patients with myelodysplastic syndrome (MDS) with a high risk of leukemia. The HOVON Central Office has already approved a protocol concept, and this agreement enables HOVON to commit staff to the planned trial in order to finalize the protocol, start regulatory and ethics reviews, and begin development of the database. Separately, GlycoMimetics said it plans to announce the design details for its company-sponsored Phase 3 trial in relapsed/refractory AML patients as part of its fourth-quarter and year-end 2017 earnings call scheduled for March 6, 2018.

Read More

Orgenesis Inc., (OTCQB:ORGS), a service and research company in the field of the regenerative medicine industry with a focus on cell therapy development and manufacturing for advanced medicinal products, today announced it has entered into an agreement with Adva Biotechnology Ltd., an innovator of enhanced bioprocessing solutions, for the development of an automated culturing system for use in the provision of contract manufacturing services, as well as Orgenesis’s therapeutic development. This system has the potential to enable cost-efficient and automated manufacturing for autologous cell therapies.

Read More

Imagine instead of a pill, a doctor prescribes a game for a child with attention deficit disorder. Or imagine patients dealing with substance abuse being prescribed assessments they can do via a mobile device to track progress.

Read More

Mid-Atlantic Angels, LLC (MAA) approaches its 2018 programming in an environment of economic optimism that leverages the economic upsurge of 2017. With the strengthening economy and accompanying confidence, angel investment is expected to surge and contribute to the growth of a vibrant regional economic landscape. The aim is to help create successful businesses while generating a return on investment for MAA member investors. In addition to scheduling a full slate of five Capital Cycles for 2018 in which entrepreneurial companies pitch for capital, MAA is adding more investor members, has lined up a valuable series of investor/entrepreneur workshops, has established a cadre of loyal sponsor organizations, is increasing its outreach to investment and entrepreneurial oriented organizations in the Frederick region, and is expanding its Board to better meet the needs of MAA and its communities.

Read More

Top life science companies perform cutting-edge research and make transformational discoveries throughout the County from the I-270 corridor of Gaithersburg and Germantown to White Oak. Add in the federal presence of the NIH and FDA, along with top talent, and tap into our strong momentum for BioHealth success. The business models vary yet our companies have important assets in common: a commitment to diversity of people, places and ideas and a spirit of innovation. Meet some of our impressive CEOs and company heads that showcase life science excellence in the County in our Think Success video series.

Read More

The University System of Maryland Board of Regents voted on Friday to approve the construction of a new engineering facility on the University of Maryland's campus.

Read More

Shepherd University has created a new nonprofit organization with a mission of helping facilitate research, innovation, and entrepreneurship. On January 24, the Internal Revenue Service approved the Shepherd Entrepreneurship and Research Corporation’s (SERC) status as a 501(c)(3).

Read More

By StartUp Health’s reckoning, New York City was the second most active city for health tech dealflow in 2017 with $1 billion invested across 63 deals. San Francisco had nearly twice the number of deals and more than three times the amount, but the closest to New York was Boston with 29.

Read More

When: Tuesday, February 13, 2018 from 5:00 PM to 7:00 PM EST

Where: Bar Louie 150 Gibbs St Rockville, MD 20850

Join BioBuzz and sponsor BioIT Solutions in Rockville at Bar Louie on February 13th, 2018 from 5 - 7pm. Only a 5 minute walk from the Rockville Metro, please join us for this exciting event. BioIT Solutions offers a range of services from enterprise systems built on their 1Platform4® Suite for advanced computational, workflow, and data management systems to IT strategy, architecture and management consulting. The 1Platform4® Suite consists of a software foundation on which various highly configurable modules are assembled and tailored to each client's specifications and needs.

Read More

Dovetailing off our Top 27 Venture Players report, we’ve put together the 19 largest AEC and real estate venture rounds of the past year. There were plenty of surprises.

Read More

Join WIB–Capital Region on February 21, 2018 for a panel discussion with industry experts that will help demystify venture capital funding in the biotech space.

Read More

Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ: DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing,

Read More

In the last six months, Personal Genome Diagnostics (PGDx) raised a $75 million series B, Harpoon Medical sold for $100 million and Sunayu acquired Fractal Technology. Which Baltimore startup is next?

Read More

The ability for cancer cells to develop resistance to chemotherapy drugs – known as multidrug resistance – remains a leading cause for tumor recurrence and cancer metastasis, but recent findings offer hope that oncologists could one day direct cancer cells to “turn off” their resistance capabilities.

Read More

SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration. Under the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen’s multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer. Under the expanded agreement, ABL will also provide development, manufacturing & QC release testing services for SillaJen’s pipeline product, JX-970.

Read More